Skip to main content

#157678

RMA.Trh4 Kb KO cells

Cat. #157678

RMA.Trh4 Kb KO cells

Cat. #: 157678

Sub-type: Primary

Unit size: 1x10^6 cells / vial

Availability: 8-10 weeks

Organism: Mouse

Tissue: Lymphatic Tissue

Disease: Cancer

Model: Knock-Out

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Thorbald Van Hall

Institute: Leiden University and Leiden University Medical Center; Stichting Oncode Institute

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: RMA.Trh4 Kb KO cells
  • Cancer: Blood cancer
  • Cancers detailed: Mouse Leukemia
  • Research fields: Cancer
  • Tool sub type: Primary
  • Parental cell: RMA
  • Organism: Mouse
  • Tissue: Lymphatic Tissue
  • Disease: Cancer
  • Model: Knock-Out
  • Description: This cell line overexpresses the ER-resident ceramide synthase Trh4 (transduced by CRISPR) and lacks the H2-Kb gene. It serves as a control in helping to understanding T-cell recognition of the Trh4-derived peptide presented by the MHC class I molecule H2-Db. This peptide-epitope is a prototypic example of a neo-antigen selectively presented by cells with processing defects in the classical MHC class I (MHC-I) pathway. RMA cells have an intact processing pathway and a functional TAP peptide transporter, but overexpress the Trh4 protein and therefore can present the Trh4 peptide. Clear T cell recognition can be observed since the irrelevant MHC class I H2-Kb was knocked out.This population acts as a clear control. CRISPR edited RMA cells.
  • Production details: Retroviral transduction of the mouse Trh4 gene in an IRES-GFP construct and CRISPR/Cas9 technology
  • Biosafety level: 1
  • Additional notes: CRISPR edited RMA cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide...
  • Recommended controls: RMA.Trh4 Db KO cells
  • Cellosaurus id: CVCL_J385

Target Details

  • Target: Trh4 Kb KO

Applications

  • Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

Handling

  • Format: Frozen
  • Growth medium: Suspension cells in DMEM+8% FCS
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

References

  • Doorduijn et al. 2018. Oncoimmunology. 7(3):e1382793. PMID: 29399388.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.